Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly

References

• World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83:373–84. PMID:18927997.
   PubMedGoogle Scholar
• Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M. Ariyoshi K; Adult Pneumonia Study Group-Japan (APSG-J). The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10(3):e0122247. doi:10.1371/journal.pone.0122247. PMID:25822890.
   PubMed Web of Science ®Google Scholar
• Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273 doi:10.1371/journal.pone.0060273. PMID:23565216.
   PubMed Web of Science ®Google Scholar
• Ministry of Internal Affairs and Communications. Current Population. Estimates as of October 1, 2016 [accessed 2017 Dec 01]. http://www.stat.go.jp/english/data/jinsui/2016np/index.htm.
   Google Scholar
• Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201:516–24. doi:10.1086/649839. PMID:20092407.
   PubMed Web of Science ®Google Scholar
• Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≥65 years. J Infect Dis. 2010;201:525–33. doi:10.1086/651131. PMID:20088694.
   PubMed Web of Science ®Google Scholar
• Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, Rueda AM, Walker ML, Hoover PA. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccine. 2011;7:919–28. doi:10.4161/hv.7.9.15996..
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine. 2011;29:2287–95. doi:10.1016/j.vaccine.2011.01.029. PMID:21255685.
   PubMed Web of Science ®Google Scholar
• Ohshima N, Nagai H, Matsui H, Akashi S, Makino T, Akeda Y, Oishi K. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine. 2014;32:1181–6. doi:10.1016/j.vaccine.2013.09.060. PMID:24120483.
   PubMed Web of Science ®Google Scholar
• Törling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine. 2003;22:96–103. doi:10.1016/S0264-410X(03)00521-8. PMID:14604576.
   PubMed Web of Science ®Google Scholar
• Caya CA, Boikos C, Desai S, Quach C. Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review. Vaccine. 2015;33(11):1302–12. doi:10.1016/j.vaccine.2015.01.060. PMID:25660650.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, Wang M, Musey L. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine. 2016;34:3875–81. doi:10.1016/j.vaccine.2016.05.052. PMID:27265450.
   PubMed Web of Science ®Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, Wichmann O, Glodny S, Hummers-Pradier E, Ledig T, Bogdan C. Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. [accessed 2018 Jan 09]. ttps://www.rki.de/EN/Content/infections/Vaccination/recommandations/Background_Paper_pneumococcal_vaccination_2016.pdf?__blob=publicationFile.
   Google Scholar
• The department of health. The expanded pneumococcal immunization program for senior citizens. [accessed 2018 Mar 05]. ttp://www.pchrd.dost.gov.ph/index.php/news/library-health-news/5480-doh-launches-pneumonia-immunization-program-for-seniors.
   Google Scholar
• CDC. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 1997;46(No. RR-8):1–24. PMID:9132580
   Google Scholar
• Green book, chapter 25, Pneumococcal. [accessed 2018 Mar 05]. ttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/674074/GB_Chapter_25_Pneumococcal_V7_0.pdf.
   Google Scholar
• The Australian Immunisation Handbook, 4.13 Pneumococcal disease. [accessed 2018 Mar 05]. ttp://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home∼handbook10part4∼handbook10-4-13#55.
   Google Scholar
• Borgoño JM, McLean AA, Vella PP, Woodhour AF, Canepa I, Davidson WL, Hilleman MR. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med. 1978;157(1):148–54. doi:10.3181/00379727-157-40010. PMID:23549.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281(3):243–8. doi:10.1001/jama.281.3.243. PMID:9918479.
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. BMC Infect Dis. 2016;16(1):711. doi:10.1186/s12879-016-2040-y. PMID:27887596.
   PubMed Web of Science ®Google Scholar
• Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, Rubinstein LJ, Caulfield MJ, Sikkema D. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol. 2009;16:387–96. doi:10.1128/CVI.00415-08. PMID:19158284.
   PubMed Web of Science ®Google Scholar
• Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004–9. doi:10.1128/CVI.00112-06. PMID:16960111.
   PubMed Web of Science ®Google Scholar